Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/97631
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Maternal allopurinol administration during suspected fetal hypoxia: a novel neuroprotective intervention? A multicentre randomised placebo controlled trial |
Author: | Kaandorp, J. Benders, M. Schuit, E. Rademaker, C. Oudijk, M. Porath, M. Oetomo, S. Wouters, M. van Elburg, R. Franssen, M. Bos, A. de Haan, T. Boon, J. de Boer, I. Rijnders, R. Jacobs, C. Scheepers, L. Gavilanes, D. Bloemenkamp, K. Rijken, M. et al. |
Citation: | Archives of Disease in Childhood: Fetal and Neonatal Edition, 2015; 100(3):F216-F223 |
Publisher: | BMJ Publishing Group |
Issue Date: | 2015 |
ISSN: | 1359-2998 1468-2052 |
Statement of Responsibility: | Joepe J Kaandorp ... Ben W J MoL ... et al. |
Abstract: | OBJECTIVE: To determine whether maternal allopurinol treatment during suspected fetal hypoxia would reduce the release of biomarkers associated with neonatal brain damage. DESIGN: A randomised double-blind placebo controlled multicentre trial. PATIENTS: We studied women in labour at term with clinical indices of fetal hypoxia, prompting immediate delivery. SETTING: Delivery rooms of 11 Dutch hospitals. INTERVENTION: When immediate delivery was foreseen based on suspected fetal hypoxia, women were allocated to receive allopurinol 500 mg intravenous (ALLO) or placebo intravenous (CONT). MAIN OUTCOME MEASURES: Primary endpoint was the difference in cord S100ß, a tissue-specific biomarker for brain damage. RESULTS: 222 women were randomised to receive allopurinol (ALLO, n=111) or placebo (CONT, n=111). Cord S100ß was not significantly different between the two groups: 44.5 pg/mL (IQR 20.2-71.4) in the ALLO group versus 54.9 pg/mL (IQR 26.8-94.7) in the CONT group (difference in median -7.69 (95% CI -24.9 to 9.52)). Post hoc subgroup analysis showed a potential treatment effect of allopurinol on the proportion of infants with a cord S100ß value above the 75th percentile in girls (ALLO n=5 (12%) vs CONT n=10 (31%); risk ratio (RR) 0.37 (95% CI 0.14 to 0.99)) but not in boys (ALLO n=18 (32%) vs CONT n=15 (25%); RR 1.4 (95% CI 0.84 to 2.3)). Also, cord neuroketal levels were significantly lower in girls treated with allopurinol as compared with placebo treated girls: 18.0 pg/mL (95% CI 12.1 to 26.9) in the ALLO group versus 32.2 pg/mL (95% CI 22.7 to 45.7) in the CONT group (geometric mean difference -16.4 (95% CI -24.6 to -1.64)). CONCLUSIONS: Maternal treatment with allopurinol during fetal hypoxia did not significantly lower neuronal damage markers in cord blood. Post hoc analysis revealed a potential beneficial treatment effect in girls. TRIAL REGISTRATION NUMBER: NCT00189007, Dutch Trial Register NTR1383. |
Keywords: | Fetal Blood Aldehydes Ketones Oxypurinol Allopurinol Xanthine Oxidase Dinoprost Enzyme Inhibitors Double-Blind Method Maternal-Fetal Exchange S100 Calcium Binding Protein beta Subunit |
Rights: | © 2015 BMJ Publishing Group |
DOI: | 10.1136/archdischild-2014-306769 |
Published version: | http://dx.doi.org/10.1136/archdischild-2014-306769 |
Appears in Collections: | Aurora harvest 7 Obstetrics and Gynaecology publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.